Deutsche Bank Aktiengesellschaft reiterated their hold rating on shares of GSK (LON:GSK – Get Rating) in a report published on Wednesday, Marketbeat Ratings reports. They currently have a GBX 1,750 ($21.44) target price on the stock.
Other research analysts also recently issued research reports about the company. Jefferies Financial Group set a GBX 2,100 ($25.73) target price on GSK in a research note on Thursday, June 23rd. Berenberg Bank boosted their target price on GSK from GBX 1,850 ($22.67) to GBX 1,950 ($23.89) and gave the company a buy rating in a research note on Thursday, July 21st. Barclays restated an equal weight rating and issued a GBX 1,800 ($22.06) target price on shares of GSK in a research note on Monday, July 18th. Citigroup restated a neutral rating and issued a GBX 1,975 ($24.20) target price on shares of GSK in a research note on Thursday, July 21st. Finally, Shore Capital restated a not rated rating on shares of GSK in a research note on Wednesday, July 27th. One analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, GSK presently has a consensus rating of Hold and an average price target of GBX 1,826.67 ($22.38).
GSK Stock Up 0.5 %
LON:GSK opened at GBX 1,667 ($20.43) on Wednesday. The firm has a market capitalization of £67.80 billion and a price-to-earnings ratio of 1,462.28. GSK has a 1-year low of GBX 1,362.80 ($16.70) and a 1-year high of GBX 1,824.40 ($22.36). The company has a current ratio of 1.43, a quick ratio of 0.35 and a debt-to-equity ratio of 97.67. The business’s fifty day moving average price is GBX 1,724.86 and its 200 day moving average price is GBX 1,687.70.
GSK Increases Dividend
Insider Transactions at GSK
In other GSK news, insider Manvinder Singh Banga acquired 647 shares of the business’s stock in a transaction that occurred on Thursday, June 23rd. The stock was acquired at an average price of GBX 1,691 ($20.72) per share, with a total value of £10,940.77 ($13,406.16). In other GSK news, insider Manvinder Singh Banga acquired 647 shares of the business’s stock in a transaction that occurred on Thursday, June 23rd. The stock was acquired at an average price of GBX 1,691 ($20.72) per share, with a total value of £10,940.77 ($13,406.16). Also, insider Emma Walmsley sold 148,525 shares of the business’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of GBX 1,763 ($21.60), for a total value of £2,618,495.75 ($3,208,547.67).
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.